HPRT1 and cancer: The results have suggested that patients with cancer with high expression of the HPRT1 gene probably were sensitive to tozasertib, teniposide, manumycin A, clofarabine, GSK‐J4, COL‐3, CD‐437, BRD‐K01737880 and 3‐Cl‐AHPC and resistant to abiraterone (Fig. 8).